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A
vorn1 noted that ‘the use of medications 
in older patients is arguably the single 
most important health care intervention 
in the industrialized world’. 
Polypharmacy and multimorbidity are com-
monplace, so ensuring that we select the right 
medicines for older patients who are at risk of 
adverse events needs to be considered carefully. 
There are a range of tools and indicators that can 
be used to assess appropriateness, and one of the 
most widely used and established sets of criteria 
are those originally developed by Beers et al.2 in 
the United States (US). 
These criteria have been applied in the study by 
Lee et al.3 whose paper is published in this issue 
of the journal. These authors determined the 
Based on the application of the Beers’ Cri-
teria, almost half of the entire sample was 
receiving at least one potentially inappropri-
ate medication, but there was no difference in 
the numbers of inappropriate medicines being 
prescribed in those patients with significant de-
pressive symptoms compared to those without 
significant symptoms. 
Drugs affecting the central nervous system domi-
nated the potentially inappropriate category and 
included amitriptyline (10 mg daily), dextropro-
poxyphene, fluoxetine, dothiepin and diazepam. 
It may not be surprising that amitriptyline was 
being prescribed in this sample of patients, but 
the dose, considered to be sub-therapeutic for de-
pression, may be used for neuropathic pain. How-
ever, there is a higher burden of side effects with 
Increasingly, there is recognition that polypharmacy is not an 
inherently bad thing. What we need to get right is the balance 
between ‘many drugs’ and ‘too many drugs’.
prevalence of potentially inappropriate medica-
tion use in a sample of community-dwelling 
older people with depressive symptoms. The 
prescribing criteria were adapted to account 
for differences in medications available in 
New Zealand compared to the US. The patient 
sample was divided into those who scored 5 or 
above on the Geriatric Depression Scale (with 
significant depressive symptoms) and those 
who had a score of 4 or less (without significant 
depressive symptoms). Polypharmacy (defined in 
this paper as the simultaneous use of 10 or more 
medicines) was identified in just under a quarter 
of participants (23%). 
amitriptyline when compared to other antidepres-
sants.4 The second most commonly prescribed 
class of potentially inappropriate medicines were 
those affecting the musculoskeletal system, such 
as naproxen and diclofenac. 
Importantly, inappropriate use was associated 
with using a greater number of medications. This 
is reflected in the literature, in that the more 
drugs a patient receives, the greater the likeli-
hood of receiving a potentially inappropriate 
drug.5 Importantly, Lee et al.3 highlight that the 
Beers’ criteria do not allow for any measurement 
of outcome as a result of using potentially inap-VOLUME 5 • NUMBER 3 • SEPTEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE 181
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propriate medicines. Indeed, a recent paper by 
Guthrie et al.6 that also used indicators to assess 
prescribing in a primary care population noted 
that prescribing of so-called ‘high-risk drugs’, 
such as tricyclic antidepressants and non-steroidal 
anti-inflammatory drugs, is not always inappro-
priate, due to the need to balance risk and benefit 
in conditions of uncertainty.
Lee et al.3 have highlighted that these types of 
prescribing indicators can act as a ‘red flag’ to 
prompt discussions around prescribing, rather 
than being simply used as a final judgment on 
the quality of prescribing. Increasingly, there is 
recognition that polypharmacy is not an inher-
ently bad thing.7 What we need to get right 
is the balance between ‘many drugs’ and ‘too 
many drugs,’7 and minimise the potential for 
adverse effects.
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